Atea Pharmaceuticals offers a late-stage, best-in-class HCV cure, with significant upside, currently trading below cash. BEM/RZR combines the advantages of current first-line HCV therapies—single pill ...
"We're proud to support the advancement of ratutrelvir from discovery through clinical development," said Ilya Baimetov, COO at ChemDiv. "By combining our integrated medicinal chemistry capabilities ...
HanchorBio Presents Two Late-Breaking Abstracts at the Society for Immunotherapy of Cancer 2025 Demonstrating Best-in-Class Potential of HCB101 in Advanced Cancers Provided by PR Newswire Nov 7, 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback